Impact of Soluble BCMA and Non-T-Cell Factors on Refractoriness to BCMA-Targeting T-Cell Engagers in Multiple Myeloma

Scientists leveraged whole genome sequencing and in vitro assays to demonstrate that soluable (s)BCMA may independently predict primary refractoriness to anti-BCMA therapies. In addition to sBCMA, tumor burden and surface BCMA antigen density collectively influence anti-BCMA TCE cytotoxic efficacy.